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Background: Nitric oxide (NO) is rapidly oxidised in humans to nitrite and nitrate, with nitrate being 
present in much greater abundance. These oxidation products can be recycled back into nitric oxide 
via a complex entero-salivary pathway, thus preserving NO activity. Approximately 65% of circulating 
nitrate is excreted in the urine in 48 hours, with the excretory pathway of the remainder unknown. 
The effect of declining renal function on nitrate clearance is unknown 
 
Methods: Forty five subjects, 21M, 24F, median age 69 (range 27-75 years) with renal function 
assessed by CKD-EPI eGFR between 9 and 89 ml/min/1.73m2 completed the study. Following a 24 h 
low nitrate diet a microplate spectrophotometric method was employed to measure plasma nitrate 
concentration and 24 h urinary nitrate excretion were measured to determine renal nitrate 
clearance.  
Results: There was a strong positive correlation between urinary nitrate clearance and eGFR, 
(Spearman R =0.7665, p<0.0001) with a moderate negative correlation between plasma nitrate 
concentration and CKD-EPI eGFR, (Spearman’s R =-0.37, p= 0.012). There was a trend between 
fractional excretion of nitrate and CKD-EPI eGFR (ml/min/1.73m2) Spearman’s R 0.27, p=0.07 though 
this did not reach statistical significance. Plasma nitrate concentration and serum creatinine 
concentration were positively correlated, Spearman’s R =0.39, p=0.008. 
 
Conclusions: We have observed a strong positive association between renal nitrate clearance and 
renal function such that plasma nitrate rises as renal function falls.  Fractional excretion of nitrate 
appears to decline as renal function falls. As such, urinary nitrate excretion is unlikely to be a reliable 














Nitric oxide (NO) is a pluripotent free radical synthesised by the nitric oxide synthase (NOS) family of 
enzymes.  The three principle isoforms endothelial, neuronal, and inducible, generate NO for the 
regulation of vascular tone, signalling, and host defence respectively [1].  Newly synthesised NO is 
rapidly oxidised to nitrite and nitrate, with nitrate being present in much greater abundance. These 
oxidation products can be recycled back into nitric oxide via a complex entero-salivary pathway [2], 
thus preserving NO activity, notably in ischemic and hypoxic conditions where it may prolong cell 
survival[3; 4]. This circulating nitrate is viewed as a store of NO by multiple researchers [5]. 
 
Little is known about nitrate clearance in man.  Nitrate readily passes through the glomerulus and is 
mostly reabsorbed by the proximal renal tubules.  In anaesthetised dogs with normal renal function, 
the volume of blood cleared of nitrate by the kidney is approximately 26 ml/min [6] [7] (for 
comparison the volume of blood cleared of creatinine in healthy humans is around 100ml/min), with 
a linear relationship between urinary nitrate excretion rate and plasma nitrate concentration [7] 
being demonstrated. Wagner et al. [6] showed that a dose of 15N isotopically-labelled nitrate is 
completely eliminated from humans in 48 hours, but only 65% is excreted in the urine;  
the fate of the other 35% remains unknown.  
 
Urinary nitrate excretion has been used as a marker of endogenous NO synthesis in multiple disease 
states [8; 9; 10; 11; 12].  The validity of this depends on the, as yet unproven, assumption that with 
changes in renal function there is no alteration in nitrate excretion by the kidneys or by non-renal 
excretory pathways.  If urinary nitrate excretion was altered by renal impairment this would make it 
an unreliable marker of NO synthesis in this setting. 
 
As it is unknown whether renal impairment affects the rate of urinary nitrate excretion, we tested 
the hypothesis that declining kidney function in man will lead to a change in urinary nitrate 
excretion.   
 
METHODS 
Ethical approval was obtained from the NRES Committee South West - Exeter Research Ethics 
Committee (14/SW/0041).  We sought to recruit fifty participants with varying degrees of renal 
function, associated with chronic kidney disease (CKD).   To enable us to test the hypothesis that 
declining renal function leads to a fall in the amount of nitrate lost in the urine we recruited 
balanced groups of healthy volunteers and patients with a breadth of renal function from the normal 
range to very severe renal impairment. Recruitment was stratified into 5 groups of 10 participants 
initially identified based on their eGFR (estimated Glomerular Filtration Rate)(ml/min/1.73m2)  as 
calculated using the CKD-EPI equation [13]. 
Group 1 Normal renal function – eGFR >60 
Group 2 Mild renal impairment - eGFR 45-59 
Group 3 Moderate renal impairment - eGFR 30-44 
Group 4 Severe renal impairment - eGFR 15-29  
Group 5 Very severe renal impairment – eGFR <15 (excluding dialysis  
patients). 
 
Subjects were invited to participate if they were between the ages of 18 and 75 and able to give 
informed consent.  Subjects were excluded if they had a body mass index (BMI) <20 or >30, were 
receiving regular therapy with organic nitrates, nicorandil, or phosphodiesterase inhibitors, had 
received antibiotic therapy within the preceding two weeks, had suffered a myocardial infarction or 
cerebro-vascular event within the preceding three months, or were current smokers (any smoking 
event in last 3 months) or were unable to give consent. Patients were also excluded from the study if 
they were on renal replacement therapy (including transplant recipients), had uncontrolled thyroid 
disease or the presence of active infection/inflammation. 
Patients were recruited from the renal unit at the Royal Devon and Exeter NHS Foundation Trust .  
After obtaining written informed consent the patients were studied in the NIHR Exeter Clinical 
Research Facility.  Healthy volunteers were recruited from databases of volunteers who had 
consented to being contacted for research studies which are held by the NIHR Exeter Clinical 
Research Facility. 
 
For two days before the study and for the twenty four hours of the urine collection participants were 
asked to follow a low nitrate diet.  Dietary advice sheets were provided.  All prescribed medications 
were continued as usual.  Participants were given instructions and materials for a twenty four hour 
urine collection at the end of their screening visit.  Participants completed a 24 hour urine collection 
in the widely accepted way, i.e., discarding the first void of the day and then collect all subsequent 
urine including the first void of the following day. At 09:00 hours, on the morning of the study day, 
they attended the study centre for a fasting blood sample and blood pressure measurement. Blood 
pressure was taken from the mean of three supine brachial measurements using an automated 
blood pressure device (Omron M6, Omron Healthcare Europe B.V. Hoofddorp, The Netherlands). 
Completed urine collections were returned to the study centre the following day.  
Assays 
Urine and plasma nitrate concentrations were measured using the VCl3/Greiss reagent based 
spectrophotometric plate method described by Miranda et al [14] and validated by our group for use 
with urine [15]. 
 
Renal nitrate clearance was calculated using the classic clearance equation: 
Cx = UxV/Px 
wherein the clearance of a substance (x) is the product of the urine concentration of x (Ux) and the 
volume of urine produced in a given time (V), divided by the plasma concentration of x (Px). 
The fractional excretion of a solute by the kidney is the amount of that solute which is filtered by the 
kidney and subsequently excreted in the urine (rather than being reabsorbed in the renal tubules).  
Fractional excretion of a solute is calculated as below. 
FEnitrate =100(nitrateurine  x creatinineplasma)/(nitrateplasma x creatinine urine) 




For the clearance study we sought to recruit 50 participants to enable us to detect a correlation 
coefficient of 0.4 or greater with 90% power, alpha=0.05. Data were analysed using Graphpad Prism 
5.  Data were analysed using non-parametric statistics 
Results 
Fifty six patients were recruited.  Eleven were withdrawn for the following reasons; intervening 
illness 2 (transient ischaemic attack, recurrent hypoglycaemia); hyponatraemia; anthropometric 
measurements outside inclusion criteria 3 (high BMI, high blood pressure, CKD-EPI eGFR higher at 
consent visit therefore falling into group already complete); excluded medications 2 (antibiotics, 
chemotherapy); unable to make time commitment 3. Data from 45 participants were included in the 
final analysis. 
Table 1. Baseline characteristics of clearance study patients 
Age (years)# 69 (59-72)  range 27-75 
BMI kg/m2* 25.6 ± 2.6 
Sex female (%) 24/45 (53%) 
Systolic BP (mm Hg)# 136 (127-144) 
Diastolic BP (mm Hg)* 78 (71-85) 
CRP (mg/l) (n=43) 35/43 = ≤2  range 1-10 
Diabetes (%) 5/45 (11%) 
 
# Median and IQR 








Figure 1. Relationship between total nitrate excretion µmol/day and CKD-EPI eGFR (ml/min/1.73m2),  
 
 


























R 0.71, p<0.0001 
 
















Figure 2: Relationships between (a) CKD-EPI eGFR (ml/min/1.73m2) and renal nitrate clearance 
(ml/min/1.73m2), Spearman’s R =0.7665, p<0.0001, (b) plasma nitrate concentration and CKD-EPI 
eGFR (ml/min/1.73m2), Spearman’s R -0.37, p=0.012, (c) Fractional excretion of nitrate and CKD-EPI 
eGFR (ml/min/1.73m2) Spearman’s R 0.27, p=0.07, (d) plasma nitrate concentration and serum 
creatinine concentration Spearman’s R of 0.39, p=0.008. 
 
There was a strong correlation between renal nitrate clearance and eGFR, Spearman R =0.7665, 
p<0.0001 with a moderate correlation between plasma nitrate concentration and eGFR, Spearman R 
=-0.37, p= 0.012.   There appeared to be a trend between fractional excretion of nitrate and CKD-EPI 
eGFR (ml/min) though this did not reach statistical significance, Spearman’s R 0.27, p=0.07.  When 
plasma nitrate concentration and serum creatinine concentration were examined an association was 
apparent with a Spearman’s R of 0.39, p=0.008. 
In the present cohort there was no evidence of a correlation between blood pressure and 24 hour 
urinary nitrate excretion (data not shown).  There was no relationship between plasma nitrate 






















R 0.27, p=0.07 
R -0.37, p=0.012 
R 0.39, p=0.008 
R =0.7665, p<0.0001 
maximum of 10 mg/l this would be expected.  Within our cohort there was no relationship between 
age and CKD-EPI eGFR, though we acknowledge this is not reflective of the general population, nor 
was there a relationship between age and nitrate clearance (see data supplement). 
A post-hoc analysis showed that across the cohort the fractional excretion rate for nitrate was 
13.0±7.4 %.  When divided across the median (CKD-EPI eGFR 38ml/min), FE nitrate was 14.22(10.97, 
17.14)% for those with the higher CKD-EPI eGFR compared with 9.78(5.16,16.39)%,p= 0.04 Mann-
Whitney test (see data supplement). 
Discussion 
We have shown that as kidney function falls, so does renal nitrate clearance.    In keeping with 
previous work we show that those with poorer kidney function have a lower total nitrate excretion 
across the 24 hour period.  Although this would conventionally be accepted as evidence for 
diminished NO synthesis in groups with pathology, our data suggest this measure in isolation will 
provide an inaccurate estimate of NO synthesis at lower eGFRs as demonstrated by more detailed 
studies of renal nitrate handling. There was an apparent trend to reduction in fractional excretion of 
nitrate at lower GFRs though this did not reach statistical significance. 
 
Data from the Framingham cohort [16] suggested a weak inverse association between plasma 
nitrate concentration and eGFR.  Our data confirm that relationship and extend it to individuals with 
very low CKD-EPI eGFR’s.   
 
Confirming that plasma nitrate concentration rises, albeit modestly, as CKD-EPI eGFR falls lends 
further credence to the idea that the weak positive association between mortality and plasma 
nitrate concentration in the Framingham cohort is largely driven renal function. Together, our study 
and the work by Maas et al [16] is at odds with the absence of a detectable difference in plasma 
nitrate concentrations from subjects on haemodialysis compared with healthy controls[17; 18].  It is 
likely that this is artefactual due to small sample sizes in the dialysis studies, though it remains 
possible that being in receipt of renal replacement therapy may alter plasma nitrate concentrations. 
 
One of the key determinants of renal excretion of a solute is the degree of tubular reabsorbtion of 
that solute.  Our data suggests that as eGFR falls, the proportion of nitrate reclaimed by the tubules 
rises though we did not observe a statistically significant correlation.  There are abundant data to 
suggest that endothelial NO synthesis is impaired in CKD by multiple mechanisms[19; 20].  It is 
possible that this more avid retention of nitrate at lower levels of renal function described in our 
study is an attempt to increase the bioavailability of NO in a setting where NO synthesis is likely to 
be impaired. Our post-hoc analysis of the fractional excretion of nitrate supports  this hypothesis. 
 
We have previously shown a relationship between blood pressure and 24 hour urinary nitrate 
excretion in 919 older adults with well-preserved renal function (eGFR >30ml/min/1.73m2) from the 
InChianti cohort[15].   No such relationship was evident in the smaller sample size studied here.  The 
most likely explanation is that for the present cohort, the impact of renal impairment on blood 
pressure is likely to be far larger than that of nitrate exposure in the InChianti cohort, where only 
those with an eGFR > 30ml/min/1.73m2 were included.  Furthermore, for the purposes of the 
present study dietary intake of nitrate was restricted which reduces the variation in nitrate 
excretion. 
 
Whilst it is known that around 65% of circulating nitrate is lost in the urine in health, the excretory 
pathway(s) for the remainder is unknown.  It is plausible that such pathways are responsible for a 
greater proportion of nitrate clearance as renal function declines.  There is evidence of intracellular 
storage of nitrate in both human and animal models with concentrations of nitrate being up to four 
times higher in muscle than in plasma[21; 22].  It is unknown whether intracellular concentrations 
are altered by differing levels of renal function.  It is also plausible that in other disease states a 
greater proportion of NO is lost to the generation of reactive nitrogen species such as peroxynitrite 
or to other reaction products such as S-nitrosothiols[23].  
 
Urinary nitrate excretion has been used to estimate NO synthesis rates in CKD[20; 24], 
hypertension[25], and congestive heart failure[26].  From the data presented here, it is clear that 24 
hour urinary nitrate excretion cannot be considered a reliable measure of total body nitric oxide 
synthesis in CKD.  This is likely to be the case in multiple other disease states.  In rheumatoid arthritis 
for example, it has previously been shown that total urinary nitrate excretion was not different 
compared with controls. In contrast serum NOx was elevated, while renal nitrate clearance rate and 
fractional excretion of NOx were lower [27].  This clearly demonstrates variation in the renal 
handling of nitrate in pathological states with a complexity that is not appreciated from the 
measurement of total nitrate excretion alone.  A small case control study of patients with primary 
pulmonary hypertension from Demonocheaux et al [28], who used an isotope enrichment 
technique, demonstrated a substantial reduction in NO synthesis but unaltered urinary nitrate 
excretion. Taken together with our data this would suggest that a reliance on 24 hour NOx excretion 




We have shown a strong positive association between renal nitrate clearance and renal function 
such that plasma nitrate rises as renal function falls.  Fractional excretion of nitrate appears to 
decline as renal function falls though this would need to be confirmed in a larger study. As such, 
urinary nitrate excretion is unlikely to be a reliable marker of endogenous NO synthesis in settings 
where renal function is altered.  
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